An epidemiologist’s perspective
There is no shortage of stuff in the media and it is hard to make sense of it all. Hope this helps!
Latest from the Blog
New wave despite vaccine success: how likely/how large?
Vaccine roll out success, coupled with adherence to behavioural rules, has led to substantial declines of infections in the UK and Israel. Increasing vaccine coverage in North America and Europe is seen also as the route back to normality. Yet infectious disease epidemiologists are still worried about a third wave causing large numbers of severe cases. Are they […]
New calculation: Risks from AstraZeneca vaccine exceed benefits in people under 30
In my post earlier today, I stated that “it is possible that the risks of cerebral venous sinus thrombosis in younger women are greater than the risks from Covid-19 infection”. This afternoon, the regulator in the UK announced the results of their detailed calculation addressing this question. This is the result of their calculation and I […]
Cerebral venous sinus thrombosis and AstraZeneca vaccine: understanding the risk
In my post on March 16, I considered the evolving information on rare blood clotting events in relation to the AstraZeneca vaccine. I concluded that the risk of pulmonary embolism, although higher with the AstraZeneca than the Pfizer vaccine, was no higher than that in the general population. Attention recently has focused on the rarer brain clotting […]
Get new content delivered directly to your inbox
